Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics

British Journal of Haematology

Volumn 170, Issue 3, 2015, Pages 305-322

  Falini, Brunangelo ^a   Sportoletti, Paolo ^a   Brunetti, Lorenzo ^a   Martelli, Maria Paola ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

acute myeloid leukaemia; epigenetic gene mutations; FLT3; normal cytogenetics; NPM1

Indexed keywords

1 [5 HYDROXY 2 (2 THIENYL) 4 QUINAZOLINYLAMINO] 3 METHYL 2,5 PYRROLEDIONE; ANTINEOPLASTIC AGENT; AR 00454200; ARSENIC TRIOXIDE; AZACITIDINE; CCT 137690; CD135 ANTIGEN; CRENOLANIB; DECITABINE; DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; LESTAURTINIB; MEMBRANE PROTEIN; MIDOSTAURIN; MONOCLONAL ANTIBODY; N CYCLOPROPYL 4 (3 THIENYL) 3 [[[[3 (TRIFLUOROMETHYL)PHENYL]AMINO]CARBONYL]AMINO]BENZENESULFONAMIDE; NUCLEOPHOSMIN; PACRITINIB; QUIZARTINIB; RETINOIC ACID; SORAFENIB; SUNITINIB; TET2 PROTEIN; UNCLASSIFIED DRUG; CD123 ANTIGEN; CD33 ANTIGEN; CD33 PROTEIN, HUMAN; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA BINDING PROTEIN; FLT3 PROTEIN, HUMAN; IDH1 PROTEIN, HUMAN; IL3RA PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; TET2 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL (TOPIC); CYTOGENETICS; DNMT3A GENE; ENZYME INHIBITION; EPIGENETICS; FLT3 GENE; GENE FUNCTION; GENE MUTATION; GENE TARGETING; HUMAN; IDH1 GENE; IDH2 GENE; NPM1 GENE; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MUTATION; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA-BINDING PROTEINS; DRUG DELIVERY SYSTEMS; EPIGENESIS, GENETIC; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MUTATION; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; SIALIC ACID BINDING IG-LIKE LECTIN 3; TRANSCRIPTION, GENETIC;

EID: 84942084798     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13409     Document Type: Review

References (164)

1. Abraham, S.A. & Holyoake, T.L. (2013) Redirecting traffic using the XPO1 police. Blood, 122, 2926–2928.
2. Alcalay, M., Tiacci, E., Bergomas, R., Bigerna, B., Venturini, E., Minardi, S.P., Meani, N., Diverio, D., Bernard, L., Tizzoni, L., Volorio, S., Luzi, L., Colombo, E., Lo Coco, F., Mecucci, C., Falini, B. & Pelicci, P.G. (2005) Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood, 106, 899–902.
3. Arber, D.A., Brunning, R.D., Le Beau, M.M., Falini, B., Vardiman, J.W., Porwit, A., Thiele, J. & Bloomfield, C.D. (2008) Acute myeloid leukaemia with recurrent genetic abnormalities. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (eds. by Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardima J.W.), pp. 110–123. International Agency for Research on Cancer (IARC), Lyon, France.
4. Aumann, S. & Abdel-Wahab, O. (2014) Somatic alterations and dysregulation of epigenetic modifiers in cancers. Biochemical and Biophysical Research Communications, 455, 24–34.
5. Bacher, U., Haferlach, C., Kern, W., Haferlach, T. & Schnittger, S. (2008) Prognostic relevance of FLT3-TKD mutations in AML: the combination matters–an analysis of 3082 patients. Blood, 111, 2527–2537.
6. Bagrintseva, K., Geisenhof, S., Kern, R., Eichenlaub, S., Reindl, C., Ellwart, J.W., Hiddemann, W. & Spiekermann, K. (2005) FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L). Blood, 105, 3679–3685.
7. Balusu, R., Fiskus, W., Rao, R., Chong, D.G., Nalluri, S., Mudunuru, U., Ma, H., Chen, L., Venkannagari, S., Ha, K., Abhyankar, S., Williams, C., McGuirk, J., Khoury, H.J., Ustun, C. & Bhalla, K.N. (2011) Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. Blood, 118, 3096–3106.
8. Bejar, R., Lord, A., Stevenson, K., Bar-Natan, M., Pérez-Ladaga, A., Zaneveld, J., Wang, H., Caughey, B., Stojanov, P., Getz, G., Garcia-Manero, G., Kantarjian, H., Chen, R., Stone, R.M., Neuberg, D., Steensma, D.P. & Ebert, B.L. (2014) TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood, 124, 2705–2712.
9. Bestor, T.H. (2000) The DNA methyltransferases of mammals. Human Molecular Genetics, 9, 2395–2402.
10. Bolli, N., Nicoletti, I., De Marco, M.F., Bigerna, B., Pucciarini, A., Mannucci, R., Martelli, M.P., Liso, A., Mecucci, C., Fabbiano, F., Martelli, M.F., Henderson, B.R. & Falini, B. (2007) Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. Cancer Research, 67, 6230–6237.
11. Borer, R.A., Lehner, C.F., Eppenberger, H.M. & Nigg, E.A. (1989) Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell, 56, 379–390.
12. Burger, K., Mühl, B., Harasim, T., Rohrmoser, M., Malamoussi, A., Orban, M., Kellner, M., Gruber-Eber, A., Kremmer, E., Hölzel, M. & Eick, D. (2010) Chemotherapeutic drugs inhibit ribosome biogenesis at various levels. Journal of Biological Chemistry, 285, 12416–12425.
13. Burnett, A.K., Hills, R.K., Green, C., Jenkinson, S., Koo, K., Patel, Y., Guy, C., Gilkes, A., Milligan, D.W., Goldstone, A.H., Prentice, A.G., Wheatley, K., Linch, D.C. & Gale, R.E. (2010) The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood, 115, 948–956.
14. Burnett, A.K., Wetzler, M. & Löwenberg, B. (2011) Therapeutic advances in acute myeloid leukemia. Journal of Clinical Oncology, 29, 487–494.
15. Busque, L., Patel, J.P., Figueroa, M.E., Vasanthakumar, A., Provost, S., Hamilou, Z., Mollica, L., Li, J., Viale, A., Heguy, A., Hassimi, M., Socci, N., Bhatt, P.K., Gonen, M., Mason, C.E., Melnick, A., Godley, L.A., Brennan, C.W., Abdel-Wahab, O. & Levine, R.L. (2012) Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nature Genetics, 44, 1179–1181.
16. Cairns, R.A. & Mak, T.W. (2013) Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discovery, 3, 730–741.
17. Cancer Genome Atlas Research Network (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New England Journal of Medicine, 368, 2059–2074.
18. Challen, G.A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J.S., Bock, C., Vasanthakumar, A., Gu, H., Xi, Y., Liang, S., Lu, Y., Darlington, G.J., Meissner, A., Issa, J.P., Godley, L.A., Li, W. & Goodell, M.A. (2012) Dnmt3a is essential for hematopoietic stem cell differentiation. Nature Genetics, 44, 23–31.
19. Chan, S.M., Thomas, D., Corces-Zimmerman, M.R., Xavy, S., Rastogi, S., Hong, W.J., Zhao, F., Medeiros, B.C., Tyvoll, D.A. & Majeti, R. (2015) Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nature Medicine, 21, 178–184.
20. Chaturvedi, A., Araujo Cruz, M.M., Jyotsana, N., Sharma, A., Yun, H., Görlich, K., Wichmann, M., Schwarzer, A., Preller, M., Thol, F., Meyer, J., Haemmerle, R., Struys, E.A., Jansen, E.E., Modlich, U., Li, Z., Sly, L.M., Geffers, R., Lindner, R., Manstein, D.J., Lehmann, U., Krauter, J., Ganser, A. & Heuser, M. (2013) Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood, 122, 2877–2887.
21. Chen, C., Liu, Y., Lu, C., Cross, J.R., Morris, J.P., 4th, Shroff, A.S., Ward, P.S., Bradner, J.E., Thompson, C. & Lowe, S.W. (2013a) Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes & Development, 27, 1974–1985.
22. Chen, Q., Chen, Y., Bian, C., Fujiki, R. & Yu, X. (2013b) TET2 promotes histone O-GlcNAcylation during gene transcription. Nature, 493, 561–564.
23. Cheng, K., Sportoletti, P., Ito, K., Clohessy, J.G., Teruya-Feldstein, J., Kutok, J.L. & Pandolfi, P.P. (2010) The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model. Blood, 115, 3341–3345.
24. Chevallier, P., Prebet, T., Pigneux, A., Hunault, M., Delaunay, J., Perry, F., Lode, L., Richebourg, S., Blanchet, O., Vey, N., Ifrah, N., Milpied, N., Blaise, D., Harousseau, J.L. & Mohty, M. (2010) Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin. Leukemia, 24, 467–469.
25. Chou, S.H., Ko, B.S., Chiou, J.S., Hsu, Y.C., Tsai, M.H., Chiu, Y.C., Yu, I.S., Lin, S.W., Hou, H.A., Kuo, Y.Y., Lin, H.M., Wu, M.F., Chou, W.C. & Tien, H.F. (2012) A knock-in Npm1 mutation in mice results in myeloproliferation and implies a perturbation in hematopoietic microenvironment. PLoS ONE, 7, e49769.
26. Choudhary, C., Schwäble, J., Brandts, C., Tickenbrock, L., Sargin, B., Kindler, T., Fischer, T., Berdel, W.E., Müller-Tidow, C. & Serve, H. (2005) AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood, 106, 265–273.
27. Chowdhury, R., Yeoh, K.K., Tian, Y.M., Hillringhaus, L., Bagg, E.A., Rose, N.R., Leung, I.K., Li, X.S., Woon, E.C., Yang, M., McDonough, M.A., King, O.N., Clifton, I.J., Klose, R.J., Claridge, T.D., Ratcliffe, P.J., Schofield, C.J. & Kawamura, A. (2011) The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Reports, 12, 463–469.
28. Corces-Zimmerman, M.R., Hong, W.J., Weissman, I.L., Medeiros, B.C. & Majeti, R. (2014) Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proceeding of The National Academy of Science of the United States of America, 111, 2548–2553.
29. Cortes, J.E., Perl, A.E., Dombret, H., Kayser, S., Steffen, B., Rousselot, P., Martinelli, G., Estey, E.H., Burnett, A.K., Gammon, G., Trone, D., Leo, E. & Levis, M.J. (2012) Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients >= 60 years of age with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts), 120, 48.
30. Cortes, J.E., Tallman, M.S., Schiller, G., Trone, D., Gammon, G., Goldberg, S., Perl, A.E., Marie, J.P., Martinelli, G. & Levis, M.J. (2013a) Results of a Phase 2 randomized, open-label, study of lower doses of quizartinib (AC220; ASP2689) in subjects with FLT3-ITD positive relapsed or refractory acute myeloid leukemia (AML). Blood (ASH Annual Meeting Abstracts), 122, 494.
31. Cortes, J.E., Kantarjian, H., Foran, J.M., Ghirdaladze, D., Zodelava, M., Borthakur, G., Gammon, G., Trone, D., Armstrong, R.C., James, J. & Levis, M. (2013b) Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. Journal of Clinical Oncology, 31, 3681–3687.
32. Couronne, L., Bastard, C. & Bernard, O.A. (2012) TET2 and DNMT3A mutations in human T-cell lymphoma. New England Journal of Medicine, 366, 95–96.
33. Damm, F., Markus, B., Thol, F., Morgan, M., Göhring, G., Schlegelberger, B., Krauter, J., Heuser, M., Bernard, O.A. & Ganser, A. (2014) TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns. Genes Chromosomes Cancer, 53, 824–832.
34. Dang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M., Fantin, V.R., Jang, H.G., Jin, S., Keenan, M.C., Marks, K.M., Prins, R.M., Ward, P.S., Yen, K.E., Liau, L.M., Rabinowitz, J.D., Cantley, L.C., Thompson, C.B., Vander Heiden, M.G. & Su, S.M. (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 462, 739–744.
35. Davis, M.I., Gross, S., Shen, M., Straley, K.S., Pragani, R., Lea, W.A., Popovici-Muller, J., DeLaBarre, B., Artin, E., Thorne, N., Auld, D.S., Li, Z., Dang, L., Boxer, M.B. & Simeonov, A. (2014) Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1. Journal of Biological Chemistry, 289, 13717–13725.
36. DiNardo, C.D., Patel, K.P., Garcia-Manero, G., Luthra, R., Pierce, S., Borthakur, G., Jabbour, E., Kadia, T., Pemmaraju, N., Konopleva, M., Faderl, S., Cortes, J., Kantarjian, H.M. & Ravandi, F. (2014) Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leukaemia & Lymphoma, 55, 1925–1929.
37. Döhner, H. & Gaidzik, V.I. (2011) Impact of genetic features on treatment decisions in AML. Hematology / the Education Program of the American Society of Hematology, 2011, 36–42.
38. Döhner, H., Estey, E.H., Amadori, S., Appelbaum, F.R., Buchner, T., Burnett, A.K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R.A., Lo-Coco, F., Naoe, T., Niederwieser, D., Ossenkoppele, G.J., Sanz, M.A., Sierra, J., Tallman, M.S., Löwenberg, B. & Bloomfield, C.D. (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, 115, 453–474.
39. Ehninger, A., Kramer, M., Röllig, C., Thiede, C., Bornhauser, M., von Bonin, M., Wermke, M., Feldmann, A., Bachmann, M., Ehninger, G. & Oelschlägel, U. (2014) Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer Journal, 4, e218.
40. El Hajj, H., Dassouki, Z., Berthier, C., Raffoux, E., Ades, L., Legrand, O., Hleihel, R., Sahin, U., Tawil, N., Salameh, A., Zibara, K., Darwiche, N., Mohty, M., Dombret, H., Fenaux, P., de Thé, H. & Bazarbachi, A. (2015) Retinoic acid and arsenic trioxide trigger degradation of mutated NPM-1 resulting in apoptosis of AML cells. Blood, pii: blood-2014-11-612416.
41. Elhammali, A., Ippolito, J.E., Collins, L., Crowley, J., Marasa, J. & Piwnica-Worms, D. (2014) A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor. Cancer Discovery, 4, 828–839.
42. Emadi, A., Jun, S.A., Tsukamoto, T., Fathi, A.T., Minden, M.D. & Dang, C.V. (2014) Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Experimental Hematology, 42, 247–251.
43. Falini, B. & Martelli, M.P. (2011) NPM1-mutated AML: targeting by disassembling. Blood, 118, 2936–2938.
44. Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., Bigerna, B., Pacini, R., Pucciarini, A., Liso, A., Vignetti, M., Fazi, P., Meani, N., Pettirossi, V., Saglio, G., Mandelli, F., Lo-Coco, F., Pelicci, P.G. & Martelli, M.F. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. New England Journal of Medicine, 352, 254–266.
45. Falini, B., Bolli, N., Shan, J., Martelli, M.P., Liso, A., Pucciarini, A., Bigerna, B., Pasqualucci, L., Mannucci, R., Rosati, R., Gorello, P., Diverio, D., Roti, G., Tiacci, E., Cazzaniga, G., Biondi, A., Schnittger, S., Haferlach, T., Hiddemann, W., Martelli, M.F., Gu, W., Mecucci, C. & Nicoletti, I. (2006a) Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood, 107, 4514–4523.
46. Falini, B., Martelli, M.P., Bolli, N., Bonasso, R., Ghia, E., Pallotta, M.T., Diverio, D., Nicoletti, I., Pacini, R., Tabarrini, A., Galletti, B.V., Mannucci, R., Roti, G., Rosati, R., Specchia, G., Liso, A., Tiacci, E., Alcalay, M., Luzi, L., Volorio, S., Bernard, L., Guarini, A., Amadori, S., Mandelli, F., Pane, F., Lo-Coco, F., Saglio, G., Pelicci, P.G., Martelli, M.F. & Mecucci, C. (2006b) Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood, 108, 1999–2005.
47. Falini, B., Nicoletti, I., Martelli, M.F. & Mecucci, C. (2007) Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood, 109, 874–885.
48. Falini, B., Mecucci, C., Saglio, G., Lo Coco, F., Diverio, D., Brown, P., Pane, F., Mancini, M., Martelli, M.P., Pileri, S., Haferlach, T., Haferlach, C. & Schnittger, S. (2008) NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. Haematologica, 93, 439–442.
49. Falini, B., Bolli, N., Liso, A., Martelli, M.P., Mannucci, R., Pileri, S. & Nicoletti, I. (2009) Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia, 23, 1731–1743.
50. Falini, B., Martelli, M.P., Bolli, N., Sportoletti, P., Liso, A., Tiacci, E. & Haferlach, T. (2011a) Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood, 117, 1109–1120.
51. Falini, B., Gionfriddo, I., Cecchetti, F., Ballanti, S., Pettirossi, V. & Martelli, M.P. (2011b) Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy? Blood Reviews, 25, 247–254.
52. Fathi, A.T., Arowojolu, O., Swinnen, I., Sato, T., Rajkhowa, T., Small, D., Marmsater, F., Robinson, J.E., Gross, S.D., Martinson, M., Allen, S., Kallan, N.C. & Levis, M. (2012) A potential therapeutic target for FLT3-ITD AML: PIM1 kinase. Leukemia Research, 36, 224–231.
53. Federici, L. & Falini, B. (2013) Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization. Protein Science, 22, 545–556.
54. Figueroa, M.E., Lugthart, S., Li, Y., Erpelinck-Verschueren, C., Deng, X., Christos, P.J., Schifano, E., Booth, J., van Putten, W., Skrabanek, L., Campagne, F., Mazumdar, M., Greally, J.M., Valk, P.J., Löwenberg, B., Delwel, R. & Melnick, A. (2010a) DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell, 17, 13–27.
55. Figueroa, M.E., Abdel-Wahab, O., Lu, C., Ward, P.S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H.F., Tallman, M.S., Sun, Z., Wolniak, K., Peeters, J.K., Liu, W., Choe, S.E., Fantin, V.R., Paietta, E., Löwenberg, B., Licht, J.D., Godley, L.A., Delwel, R., Valk, P.J., Thompson, C.B., Levine, R.L. & Melnick, A. (2010b) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell, 18, 553–567.
56. Gaidzik, V.I., Paschka, P., Späth, D., Habdank, M., Köhne, C.H., Germing, U., von Lilienfeld-Toal, M., Held, G., Horst, H.A., Haase, D., Bentz, M., Götze, K., Döhner, H., Schlenk, R.F., Bullinger, L. & Döhner, K. (2012) TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. Journal of Clinical Oncology, 30, 1350–1357.
57. Gaidzik, V.I., Schlenk, R.F., Paschka, P., Stölzle, A., Späth, D., Kuendgen, A., von Lilienfeld-Toal, M., Brugger, W., Derigs, H.G., Kremers, S., Greil, R., Raghavachar, A., Ringhoffer, M., Salih, H.R., Wattad, M., Kirchen, H.G., Runde, V., Heil, G., Petzer, A.L., Girschikofsky, M., Heuser, M., Kayser, S., Goehring, G., Teleanu, M.V., Schlegelberger, B., Ganser, A., Krauter, J., Bullinger, L., Döhner, H. & Döhner, K. (2013) Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood, 121, 4769–4777.
58. Galanis, A., Ma, H., Rajkhowa, T., Ramachandran, A., Small, D., Cortes, J. & Levis, M. (2014) Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood, 123, 94–100.
59. Garzon, R., Garofalo, M., Martelli, M.P., Briesewitz, R., Wang, L., Fernandez-Cymering, C., Volinia, S., Liu, C.G., Schnittger, S., Haferlach, T., Liso, A., Diverio, D., Mancini, M., Meloni, G., Foa, R., Martelli, M.F., Mecucci, C., Croce, C.M. & Falini, B. (2008) Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proceedings of the National Academy of Sciences of the United States of America, 105, 3945–3950.
60. Garzon, R., Volinia, S., Papaioannou, D., Nicolet, D., Kohlschmidt, J., Yan, P.S., Mrózek, K., Bucci, D., Carroll, A.J., Baer, M.R., Wetzler, M., Carter, T.H., Powell, B.L., Kolitz, J.E., Moore, J.O., Eisfeld, A.K., Blachly, J.S., Blum, W., Caligiuri, M.A., Stone, R.M., Marcucci, G., Croce, C.M., Byrd, J.C. & Bloomfield, C.D. (2014) Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 111, 18679–18684.
61. Griessinger, E., Imbert, V., Lagadec, P., Gonthier, N., Dubreuil, P., Romanelli, A., Dreano, M. & Peyron, J.F. (2007) AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells. Leukemia, 21, 877–885.
62. Grisendi, S., Bernardi, R., Rossi, M., Cheng, K., Khandker, L., Manova, K. & Pandolfi, P.P. (2005) Role of nucleophosmin in embryonic development and tumorigenesis. Nature, 437, 147–153.
63. Grisendi, S., Mecucci, C., Falini, B. & Pandolfi, P.P. (2006) Nucleophosmin and cancer. Nature Reviews Cancer, 6, 493–505.
64. Gross, S., Cairns, R.A., Minden, M.D., Driggers, E.M., Bittinger, M.A., Jang, H.G., Sasaki, M., Jin, S., Schenkein, D.P., Su, S.M., Dang, L., Fantin, V.R. & Mak, T.W. (2010) Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. Journal of Experimental Medicine, 207, 339–344.
65. Grossmann, V., Tiacci, E., Holmes, A.B., Kohlmann, A., Martelli, M.P., Kern, W., Spanhol-Rosseto, A., Klein, H.U., Dugas, M., Schindela, S., Trifonov, V., Schnittger, S., Haferlach, C., Bassan, R., Wells, V.A., Spinelli, O., Chan, J., Rossi, R., Baldoni, S., De Carolis, L., Goetze, K., Serve, H., Peceny, R., Kreuzer, K.A., Oruzio, D., Specchia, G., Di Raimondo, F., Fabbiano, F., Sborgia, M., Liso, A., Farinelli, L., Rambaldi, A., Pasqualucci, L., Rabadan, R., Haferlach, T. & Falini, B. (2011) Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood, 118, 6153–6163.
66. Grossmann, V., Haferlach, C., Weissmann, S., Roller, A., Schindela, S., Poetzinger, F., Stadler, K., Bellos, F., Kern, W., Haferlach, T., Schnittger, S. & Kohlmann, A. (2013) The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL. Genes Chromosomes Cancer, 52, 410–422.
67. Grundler, R., Miething, C., Thiede, C., Peschel, C. & Duyster, J. (2005) FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood, 105, 4792–4799.
68. Grunwald, M.R. & Levis, M.J. (2013) FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. International Journal of Hematology, 97, 683–694.
69. Hatzimichael, E., Tsolas, E. & Briasoulis, E. (2014) Profile of pacritinib and its potential in the treatment of hematologic disorders. Journal of Blood Medicine, 9, 143–152.
70. He, X. & Zhang, J. (2006) Why do hubs tend to be essential in protein networks? PLoS Genetics, 2, e88.
71. He, Y.F., Li, B.Z., Li, Z., Liu, P., Wang, Y., Tang, Q., Ding, J., Jia, Y., Chen, Z., Li, L., Sun, Y., Li, X., Dai, Q., Song, C.X., Zhang, K., He, C. & Xu, G.L. (2011) Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science, 333, 1303–1307.
72. Heidel, F., Solem, F.K., Breitenbuecher, F., Lipka, D.B., Kasper, S., Thiede, M.H., Brandts, C., Serve, H., Roesel, J., Giles, F., Feldman, E., Ehninger, G., Schiller, G.J., Nimer, S., Stone, R.M., Wang, Y., Kindler, T., Cohen, P.S., Huber, C. & Fischer, T. (2006) Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood, 107, 293–300.
73. Holz-Schietinger, C., Matje, D.M. & Reich, N.O. (2012) Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation. Journal of Biological Chemistry, 287, 30941–30951.
74. Itzykson, R., Kosmider, O., Cluzeau, T., Mansat-De Mas, V., Dreyfus, F., Beyne-Rauzy, O., Quesnel, B., Vey, N., Gelsi-Boyer, V., Raynaud, S., Preudhomme, C., Ades, L., Fenaux, P. & Fontenay, M. (2011) Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia, 25, 1147–1152.
75. Janin, M., Mylonas, E., Saada, V., Micol, J.B., Renneville, A., Quivoron, C., Koscielny, S., Scourzic, L., Forget, S., Pautas, C., Caillot, D., Preudhomme, C., Dombret, H., Berthon, C., Barouki, R., Rabier, D., Auger, N., Griscelli, F., Chachaty, E., Leclercq, E., Courtier, M.H., Bennaceur-Griscelli, A., Solary, E., Bernard, O.A., Penard-Lacronique, V., Ottolenghi, C. & de Botton, S. (2014) Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. Journal of Clinical Oncology, 32, 297–305.
76. Jaseliec, J., Saloura, V. & Godley, L.A. (2014) The mechanistic role of DNA methylation in myeloid leukemogenesis. Leukemia, 28, 1765–1773.
77. Jurkowska, R.Z., Jurkowski, T.P. & Jeltsch, A. (2011) Structure and function of mammalian DNA methyltransferases. Chembiochem : A European Journal of Chemical Biology, 12, 206–222.
78. Kampa-Schittenhelm, K.M., Heinrich, M.C., Akmut, F., Döhner, H., Döhner, K. & Schittenhelm, M.M. (2013) Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. Molecular Cancer, 12, 19.
79. Kandoth, C., McLellan, M.D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J.F., Wyczalkowski, M.A., Leiserson, M.D., Miller, C.A., Welch, J.S., Walter, M.J., Wendl, M.C., Ley, T.J., Wilson, R.K., Raphael, B.J. & Ding, L. (2013) Mutational landscape and significance across 12 major cancer types. Nature, 502, 333–339.
80. Karaman, M.W., Herrgard, S., Treiber, D.K., Gallant, P., Atteridge, C.E., Campbell, B.T., Chan, K.W., Ciceri, P., Davis, M.I., Edeen, P.T., Faraoni, R., Floyd, M., Hunt, J.P., Lockhart, D.J., Milanov, Z.V., Morrison, M.J., Pallares, G., Patel, H.K., Pritchard, S., Wodicka, L.M. & Zarrinkar, P.P. (2008) A quantitative analysis of kinase inhibitor selectivity. Nature Biotechnology, 26, 127–132.
81. Kats, L.M., Reschke, M., Taulli, R., Pozdnyakova, O., Burgess, K., Bhargava, P., Straley, K., Karnik, R., Meissner, A., Small, D., Su, S.M., Yen, K., Zhang, J. & Pandolfi, P.P. (2014) Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell, 14, 329–341.
82. Kayser, S., Schlenk, R.F., Londono, M.C., Breitenbuecher, F., Wittke, K., Du, J., Groner, S., Späth, D., Krauter, J., Ganser, A., Döhner, H., Fischer, T. & Döhner, K. (2009) Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood, 114, 2386–2392.
83. Ko, M., Bandukwala, H.S., An, J., Lamperti, E.D., Thompson, E.C., Hastie, R., Tsangaratou, A., Rajewsky, K., Koralov, S.B. & Rao, A. (2011) Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proceedings of the National Academy of Sciences of the United States of America, 108, 14566–14571.
84. Kohli, R.M. & Zhang, Y. (2013) TET enzymes, TDG and the dynamics of DNA demethylation. Nature, 502, 472–479.
85. Krönke, J., Schlenk, R.F., Jensen, K.O., Tschurtz, F., Corbacioglu, A., Gaidzik, V.I., Paschka, P., Onken, S., Eiwen, K., Habdank, M., Späth, D., Lübbert, M., Wattad, M., Kindler, T., Salih, H.R., Held, G., Nachbaur, D., von Lilienfeld-Toal, M., Germing, U., Haase, D., Mergenthaler, H.G., Krauter, J., Ganser, A., Göhring, G., Schlegelberger, B., Döhner, H. & Döhner, K. (2011) Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. Journal of Clinical Oncology, 29, 2709–2716.
86. Krönke, J., Bullinger, L., Teleanu, V., Tschürtz, F., Gaidzik, V.I., Kühn, M.W., Rücker, F.G., Holzmann, K., Paschka, P., Kapp-Schwörer, S., Späth, D., Kindler, T., Schittenhelm, M., Krauter, J., Ganser, A., Göhring, G., Schlegelberger, B., Schlenk, R.F., Döhner, H. & Döhner, K. (2013) Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood, 122, 100–108.
87. Leischner, H., Albers, C., Grundler, R., Razumovskaya, E., Spiekermann, K., Bohlander, S., Ronnstrand, L., Gotze, K., Peschel, C. & Duyster, J. (2012) SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML. Blood, 119, 4026–4033.
88. Leung, A.Y., Man, C.H. & Kwong, Y.L. (2013) FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia. Leukemia, 27, 260–268.
89. Levis, M.J. & Grunwald, M.R. (2013) FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. International Journal of Hematology, 97, 683–694.
90. Levis, M.J., Perl, A.E., Dombret, H., Döhner, H., Steffen, B., Rousselot, P., Martinelli, G., Estey, E.H., Burnett, A.K., Gammon, G., Trone, D., Leo, E. & Cortes, J.E. (2012) Final results of a phase 2 open-label, monotherapy, efficacy and safety of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation. Blood (ASH Annual Meeting Abstracts), 120, 673.
91. Ley, T.J., Ding, L., Walter, M.J., McLellan, M.D., Lamprecht, T., Larson, D.E., Kandoth, C., Payton, J.E., Baty, J., Welch, J., Harris, C.C., Lichti, C.F., Townsend, R.R., Fulton, R.S., Dooling, D.J., Koboldt, D.C., Schmidt, H., Zhang, Q., Osborne, J.R., Lin, L., O'Laughlin, M., McMichael, J.F., Delehaunty, K.D., McGrath, S.D., Fulton, L.A., Magrini, V.J., Vickery, T.L., Hundal, J., Cook, L.L., Conyers, J.J., Swift, G.W., Reed, J.P., Alldredge, P.A., Wylie, T., Walker, J., Kalicki, J., Watson, M.A., Heath, S., Shannon, W.D., Varghese, N., Nagarajan, R., Westervelt, P., Tomasson, M.H., Link, D.C., Graubert, T.A., DiPersio, J.F., Mardis, E.R. & Wilson, R.K. (2010) DNMT3A mutations in acute myeloid leukemia. New England Journal of Medicine, 363, 2424–2433.
92. Li, L., Piloto, O., Nguyen, H.B., Greenberg, K., Takamiya, K., Racke, F., Huso, D. & Small, D. (2008) Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model. Blood, 111, 3849–3858.
93. Li, L., Bailey, E., Greenblatt, S., Huso, D. & Small, D. (2011) Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knock-in mice. Blood, 118, 4935–4945.
94. Li, W., Zhang, L., Huang, L., Mi, Y. & Wang, J. (2012) Meta-analysis for the potential application of FLT3-TKD mutations as prognostic indicator in non-promyelocytic AML. Leukemia Research, 36, 186–191.
95. Linch, D.C., Hills, R.K., Burnett, A.K., Khwaja, A. & Gale, R.E. (2014) Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. Blood, 124, 273–276.
96. Liso, A., Bogliolo, A., Freschi, V., Martelli, M.P., Pileri, S.A., Santodirocco, M., Bolli, N., Martelli, M.F. & Falini, B. (2008) In human genome, generation of a nuclear export signal through duplication appears unique to nucleophosmin (NPM1) mutations and is restricted to AML. Leukemia, 22, 1285–1289.
97. Lu, C., Ward, P.S., Kapoor, G.S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C.R., Khanin, R., Figueroa, M.E., Melnick, A., Wellen, K.E., O'Rourke, D.M., Berger, S.L., Chan, T.A., Levine, R.L., Mellinghoff, I.K. & Thompson, C.B. (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature, 483, 474–478.
98. Ma, H.S., Nguyen, B., Duffield, A.S., Li, L., Galanis, A., Williams, A.B., Brown, P.A., Levis, M.J., Leahy, D.J. & Small, D. (2014) FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia. Cancer Research, 74, 5206–5217.
99. Madzo, J., Liu, H., Rodriguez, A., Vasanthakumar, A., Sundaravel, S., Caces, D.B., Looney, T.J., Zhang, L., Lepore, J.B., Macrae, T., Duszynski, R., Shih, A.H., Song, C.X., Yu, M., Grossman, R., Raumann, B., Verma, A., He, C., Levine, R.L., Lavelle, D., Lahn, B.T., Wickrema, A. & Godley, L.A. (2014) Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythopoiesis. Cell Reports, 6, 231–244.
100. Mallardo, M., Caronno, A., Pruneri, G., Raviele, P.R., Viale, A., Pelicci, P.G. & Colombo, E. (2013) NPMc+ and FLT3_ITD mutations cooperate in inducing acute leukaemia in a novel mouse model. Leukemia, 27, 2248–2251.
101. Man, C.H., Fung, T.K., Ho, C., Han, H.H., Chow, H.C., Ma, A.C., Choi, W.W., Lok, S., Cheung, A.M., Eaves, C., Kwong, Y.L. & Leung, A.Y. (2012) Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood, 119, 5133–5143.
102. Marcucci, G., Maharry, K., Wu, Y.Z., Radmacher, M.D., Mrózek, K., Margeson, D., Holland, K.B., Whitman, S.P., Becker, H., Schwind, S., Metzeler, K.H., Powell, B.L., Carter, T.H., Kolitz, J.E., Wetzler, M., Carroll, A.J., Baer, M.R., Caligiuri, M.A., Larson, R.A. & Bloomfield, C.D. (2010) IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of Clinical Oncology, 28, 2348–2355.
103. Marcucci, G., Metzeler, K.H., Schwind, S., Becker, H., Maharry, K., Mrózek, K., Radmacher, M.D., Kohlschmidt, J., Nicolet, D., Whitman, S.P., Wu, Y.Z., Powell, B.L., Carter, T.H., Kolitz, J.E., Wetzler, M., Carroll, A.J., Baer, M.R., Moore, J.O., Caligiuri, M.A., Larson, R.A. & Bloomfield, C.D. (2012) Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. Journal of Clinical Oncology, 30, 742–750.
104. Mardis, E.R., Ding, L., Dooling, D.J., Larson, D.E., McLellan, M.D., Chen, K., Koboldt, D.C., Fulton, R.S., Delehaunty, K.D., McGrath, S.D., Fulton, L.A., Locke, D.P., Magrini, V.J., Abbott, R.M., Vickery, T.L., Reed, J.S., Robinson, J.S., Wylie, T., Smith, S.M., Carmichael, L., Eldred, J.M., Harris, C.C., Walker, J., Peck, J.B., Du, F., Dukes, A.F., Sanderson, G.E., Brummett, A.M., Clark, E., McMichael, J.F., Meyer, R.J., Schindler, J.K., Pohl, C.S., Wallis, J.W., Shi, X., Lin, L., Schmidt, H., Tang, Y., Haipek, C., Wiechert, M.E., Ivy, J.V., Kalicki, J., Elliott, G., Ries, R.E., Payton, J.E., Westervelt, P., Tomasson, M.H., Watson, M.A., Baty, J., Heath, S., Shannon, W.D., Nagarajan, R., Link, D.C., Walter, M.J., Graubert, T.A., DiPersio, J.F., Wilson, R.K. & Ley, T.J. (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. New England Journal of Medicine, 361, 1058–1066.
105. Martelli, M.P., Pettirossi, V., Thiede, C., Bonifacio, E., Mezzasoma, F., Cecchini, D., Pacini, R., Tabarrini, A., Ciurnelli, R., Gionfriddo, I., Manes, N., Rossi, R., Giunchi, L., Oelschlagel, U., Brunetti, L., Gemei, M., Delia, M., Specchia, G., Liso, A., Di Ianni, M., Di Raimondo, F., Falzetti, F., Del Vecchio, L., Martelli, M.F. & Falini, B. (2010) CD34 + cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood, 116, 3907–3922.
106. Martelli, M.P., Sportoletti, P., Tiacci, E., Martelli, M.F. & Falini, B. (2013) Mutational landscape of AML with normal cytogenetics: biological and clinical implications. Blood Reviews, 27, 13–22.
107. Martelli, M.P., Gionfriddo, I., Mezzasoma, F., Milano, F., Pierangeli, S., Mulas, F., Pacini, R., Tabarrini, A., Pettirossi, V., Rossi, R., Vetro, C., Brunetti, L., Sportoletti, P., Tiacci, E., Di Raimondo, F. & Falini, B. (2015) Arsenic trioxide and all-trans-retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. Blood, pii: blood-2014-11-611459.
108. Matre, P., Shariati, M., Velez, J., Qi, Y., Konoplev, S., Su, X., DiNardo, C.D., Daver, N., Majeti, R., Andreeff, M., Chan, S. & Konopleva, M. (2014) Efficacy of novel glutaminase inhibitor CB-839 in acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts), 124, 3763.
109. Molenaar, R.J., Radivoyevitch, T., Maciejewski, J.P., van Noorden, C.J. & Bleeker, F.E. (2014) The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. Biochimica et Biophysica Acta, 1846, 326–341.
110. Moore, A.S., Faisal, A., Gonzalez de Castro, D., Bavetsias, V., Sun, C., Atrash, B., Valenti, M., de Haven Brandon, A., Avery, S., Mair, D., Mirabella, F., Swansbury, J., Pearson, A.D., Workman, P., Blagg, J., Raynaud, F.I., Eccles, S.A. & Linardopoulos, S. (2012) Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia, 26, 1462–1470.
111. Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M.E., Vasanthakumar, A., Patel, J., Zhao, X., Perna, F., Pandey, S., Madzo, J., Song, C., Dai, Q., He, C., Ibrahim, S., Beran, M., Zavadil, J., Nimer, S.D., Melnick, A., Godley, L.A., Aifantis, I. & Levine, R.L. (2011) Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell, 20, 11–24.
112. Mupo, A., Celani, L., Dovey, O., Cooper, J.L., Grove, C., Rad, R., Sportoletti, P., Falini, B., Bradley, A. & Vassiliou, G.S. (2013) A powerful molecular synergy between mutant nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice. Leukemia, 27, 1917–1920.
113. Nakajima, H. & Kunimoto, H. (2014) TET2 as an epigenetic master regulator for normal and malignant hematopoiesis. Cancer Science, 105, 1093–1099.
114. Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T. & Misawa, S. (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia, 10, 1911–1918.
115. Okano, M., Bell, D.W., Haber, D.A. & Li, E. (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell, 99, 247–257.
116. Okuwaki, M. (2008) The structure and functions of NPM1/Nucleophsmin/B23, a multifunctional nucleolar acidic protein. Journal of Biochemistry, 143, 441–448.
117. Ossenkoppele, G. & Löwenberg, B. (2015) How I treat the older patient with acute myeloid leukemia. Blood, 125, 767–774.
118. Pasqualucci, L., Liso, A., Martelli, M.P., Bolli, N., Pacini, R., Tabarrini, A., Carini, M., Bigerna, B., Pucciarini, A., Mannucci, R., Nicoletti, I., Tiacci, E., Meloni, G., Specchia, G., Cantore, N., Di Raimondo, F., Pileri, S., Mecucci, C., Mandelli, F., Martelli, M.F. & Falini, B. (2006) Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification. Blood, 108, 4146–4155.
119. Patel, J.P., Gonen, M., Figueroa, M.E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., Huberman, K., Cheng, J., Viale, A., Socci, N.D., Heguy, A., Cherry, A., Vance, G., Higgins, R.R., Ketterling, R.P., Gallagher, R.E., Litzow, M., van den Brink, M.R., Lazarus, H.M., Rowe, J.M., Luger, S., Ferrando, A., Paietta, E., Tallman, M.S., Melnick, A., Abdel-Wahab, O. & Levine, R.L. (2012) Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. New England Journal of Medicine, 366, 1079–1089.
120. Peterlin, P., Renneville, A., Ben Abdelali, R., Nibourel, O., Thomas, X., Pautas, C., deBottom, S., Raffoux, E., Cayuela, J-M., Boissel, N., Terrè, C., Celli-Lebras, K., Castaigne, S., Preudhomme, C., Gardin, C. & Dombret, H. (2015) Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia. Haematologica, doi:10.3324/haematol.2014.115576
121. Pløen, G.G., Nederby, L., Guldberg, P., Hanse, M., Ebbesen, L.H., Jensen, U.B., Hokland, P. & Aggerholm, A. (2014) Persistence of DNMT3A mutations at long-term remission in adult patients with AML. British Journal of Haematology, 167, 478–486.
122. Pratcorona, M., Brunet, S., Nomdedeu, J., Ribera, J.M., Tormo, M., Duarte, R., Escoda, L., Guardia, R., Queipo de Llano, M.P., Salamero, O., Bargay, J., Pedro, C., Marti, J.M., Torrebadell, M., Diaz-Beya, M., Camos, M., Colomer, D., Hoyos, M., Sierra, J. & Esteve, J. (2013) Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood, 121, 2734–2738.
123. Quivoron, C., Couronne, L., Della Valle, V., Lopez, C.K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.H., Godley, L., Opolon, P., Tilly, H., Solary, E., Duffourd, Y., Dessen, P., Merle-Beral, H., Nguyen-Khac, F., Fontenay, M., Vainchenker, W., Bastard, C., Mercher, T. & Bernard, O.A. (2011) TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell, 20, 25–38.
124. Rambaldi, A., Biagi, E., Bonini, C., Biondi, A. & Introna, M. (2015) Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. Leukemia, 29, 1–10.
125. Rampal, R., Alkalin, A., Madzo, J., Vasanthakumar, A., Pronier, E., Patel, J., Li, Y., Ahn, J., Abdel-Wahab, O., Shih, A., Lu, C., Ward, P.S., Tsai, J.J., Hricik, T., Tosello, V., Tallman, J.E., Zhao, X., Daniels, D., Dai, Q., Cimino, L., Aifantis, I., He, C., Fuks, F., Tallman, M.S., Ferrando, A., Nimer, S., Paietta, E., Thompson, C.B., Licht, J.D., Mason, C.E., Godley, L.A., Melnick, A., Figueroa, M.E. & Levine, R.L. (2014) DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Reports, 11, 1841–1855.
126. Rau, R., Magoon, D., Greenblatt, S., Li, L., Annesley, C., Duffield, A.S., Huso, D., McIntyre, E., Clohessy, J.G., Reschke, M., Pandolfi, P.P., Small, D. & Brown, P. (2014) NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease. Experimental Hematology, 42, e105.
127. Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., Kunii, K., Pedraza, A., Schalm, S., Silverman, L., Miller, A., Wang, F., Yang, H., Chen, Y., Kernytsky, A., Rosenblum, M.K., Liu, W., Biller, S.A., Su, S.M., Brennan, C.W., Chan, T.A., Graeber, T., Yen, K.E. & Mellinghoff, I.K. (2013) An Inhibitor of IDH1 delays growth and promotes differentiation of glioma cells. Science, 349, 626–630.
128. Russler-Germain, D.A., Spencer, D.H., Young, M.A., Lamprecht, T.L., Miller, C.A., Fulton, R., Meyer, M.R., Erdmann-Gilmore, P., Townsend, R.R., Wilson, R.K. & Ley, T.J. (2014) The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell, 25, 442–454.
129. Sarkaria, S.M., Christopher, M.J., Klco, J.M. & Ley, T.J. (2014) Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro. Leukemia, 28, 2403–2406.
130. Sasaki, M., Knobbe, C.B., Munger, J.C., Lind, E.F., Brenner, D., Brüstle, A., Harris, I.S., Holmes, R., Wakeham, A., Haight, J., You-Ten, A., Li, W.Y., Schalm, S., Su, S.M., Virtanen, C., Reifenberger, G., Ohashi, P.S., Barber, D.L., Figueroa, M.E., Melnick, A., Zúñiga-Pflücker, J.C. & Mak, T.W. (2012) IDH1 (R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature, 488, 656–659.
131. Sato, T., Yang, X., Knapper, S., White, P., Smith, B.D., Galkin, S., Small, D., Burnett, A. & Levis, M. (2011) FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood, 117, 3286–3293.
132. Schlenk, R.F., Döhner, K., Kneba, M., Götze, K., Hartmann, F., Del Valle, F., Kirchen, H., Koller, E., Fischer, J.T., Bullinger, L., Habdank, M., Späth, D., Groner, S., Krebs, B., Kayser, S., Corbacioglu, A., Anhalt, A., Benner, A., Fröhling, S. & Döhner, H. (2009) Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica, 94, 54–60.
133. Schlenk, R.F., Döhner, K., Krauter, J., Gaidzik, V., Paschka, P., Heuser, M., Kindler, T., Lubbert, M., Martin, H., Salih, H.R., Kuendgen, A., Horst, H.A., Von Lilienfeld-Toal, M., Götze, K., Nachbaur, D., Watted, M., Köhne, C.H., Fiedler, W., Bentz, M., Wulf, G., Held, G., Hertenstein, B., Mergenthaler, H.G., Salwender, H., Rummel, M.J., Raghavachar, A., Benner, A., Schlegelberger, B., Ganser, A. & Döhner, H. (2011) All-Trans retinoic acid improves outcome in younger adult patients with nucleophosmin-1 mutated acute myeloid leukemia, results of the AMLSG 07-04 randomized treatment trial. Blood (ASH Annual Meeting Abstracts), 118, 80.
134. Schoofs, T., Berdel, W.E. & Müller-Tidow, C. (2014) Origins of aberrant DNA methylation in acute myeloid leukemia. Leukemia, 28, 1–14.
135. Sehgal, A.R., Gimotty, P.A., Zhao, J., Hsu, J-M., Daber, R., Morrissette, J.D., Luger, S., Loren, A.W. & Carroll, M. (2015) DNMT3A mutational status affects the results of dose-escalated induction therapy in acute myelogenous leukemia. Clinical Cancer Research, Jan 21. pii: clincanres.0327.2014. [Epub ahead of print].
136. Serve, H., Krug, U., Wagner, R., Sauerland, M.C., Heinecke, A., Brunnberg, U., Schaich, M., Ottmann, O., Duyster, J., Wandt, H., Fischer, T., Giagounidis, A., Neubauer, A., Reichle, A., Aulitzky, W., Noppeney, R., Blau, I., Kunzmann, V., Stuhlmann, R., Krämer, A., Kreuzer, K.A., Brandts, C., Steffen, B., Thiede, C., Müller-Tidow, C., Ehninger, G. & Berdel, W.E. (2013) Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. Journal of Clinical Oncology, 31, 3110–3118.
137. Sexauer, A., Perl, A., Yang, X., Borowitz, M., Gocke, C., Rajkhowa, T., Thiede, C., Frattini, M., Nybakken, G.E., Pratz, K., Karp, J., Smith, B.D. & Levis, M. (2012) Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood, 120, 4205–4214.
138. Shlush, L.I., Zandi, S., Mitchell, A., Chen, W.C., Brandwein, J.M., Gupta, V., Kennedy, J.A., Schimmer, A.D., Schuh, A.C., Yee, K.W., McLeod, J.L., Doedens, M., Medeiros, J.J., Marke, R., Kim, H.J., Lee, K., McPherson, J.D., Hudson, T.J., Brown, A.M., Yousif, F., Trinh, Q.M., Stein, L.D., Minden, M.D., Wang, J.C. & Dick, J.E. (2014) Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature, 506, 328–333.
139. Smith, C.C., Wang, Q., Chin, C.S., Salerno, S., Damon, L.E., Levis, M.J., Perl, A.E., Travers, K.J., Wang, S., Hunt, J.P., Zarrinkar, P.P., Schadt, E.E., Kasarskis, A., Kuriyan, J. & Shah, N.P. (2012) Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature, 485, 260–263.
140. Smith, C.C., Lasater, E.A., Zhu, X., Lin, K.C., Stewart, W.K., Damon, L.E., Salerno, S. & Shah, N.P. (2013a) Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood, 121, 3165–3171.
141. Smith, C.C., Lin, K., Lasater, E., Stewart, W., Damon, L.E., Kasarskis, A., Bashir, A., Pendleton, M., Sebra, R., Perl, A.E., Le, M.H., Zhang, C., West, B. & Shah, N.P. (2013b) Preclinical and clinical resistance mechanisms to the investigational selective FLT3 inhibitor PLX3397 in FLT3-ITD acute myeloid leukemia (AML). Blood (ASH Annual Meeting Abstracts), 122, 3938.
142. Smith, C.C., Lasater, E.A., Lin, K.C., Wang, Q., McCreery, M.Q., Stewart, W.K., Damon, L.E., Perl, A.E., Jeschke, G.R., Sugita, M., Carroll, M., Kogan, S.C., Kuriyan, J. & Shah, N.P. (2014) Crenolanib is a selective type I pan-FLT3 inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 111, 5319–5324.
143. Sockel, K., Wermke, M., Radke, J., Kiani, A., Schaich, M., Bornhäuser, M., Ehninger, G., Thiede, C. & Platzbecker, U. (2011) Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse. Haematologica, 96, 1568–1570.
144. Sportoletti, P., Varasano, E., Rossi, R., Bereshchenko, O., Cecchini, D., Gionfriddo, I., Bolli, N., Tiacci, E., Intermesoli, T., Zanghi, P., Masciulli, A., Martelli, M.P., Falzetti, F., Martelli, M.F. & Falini, B. (2013) The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. Blood, 121, 3447–3458.
145. Sportoletti, P., Varasano, E., Rossi, R., Mupo, A., Tiacci, E., Vassiliou, G., Martelli, M.P. & Falini, B. (2015) Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications. Leukemia, 29, 269–278.
146. Stein, E.M., Altman, J.K., Collins, R., DeAngelo, D.J., Fathi, A.T., Flinn, I., Frankel, A., Levine, R.L., Medeiros, B.C., Patel, M., Pollyea, D.A., Roboz, G.J., Stone, R.M., Swords, R.T., Tallman, M.S., Agresta, S., Fan, B., Yang, H., Yen, K. & de Botton, S. (2014) AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, induces durable remissions in a Phase I study in patients with IDH2 mutation positive advanced hematologic malignancies. Blood (ASH Annual Meeting Abstracts), 124, 115.
147. Stirewalt, D.L. & Radich, J.P. (2003) The role of FLT3 in haematopoietic malignancies. Nature Reviews Cancer, 3, 650–665.
148. Sudhindra, A. & Smith, C.C. (2014) FLT3 inhibitors in AML: are we there yet? Current Hematologic Malignancy Reports, 9, 174–185.
149. Swaminathan, V., Kishore, A.H., Febitha, K.K. & Kundu, T.K. (2005) Human histone chaperone nucleophosmin enhances acetylation-dependent chromatin transcription. Molecular and Cellular Biology, 25, 7534–7545.
150. Tahiliani, M., Koh, K.P., Shen, Y., Pastor, W.A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L.M., Liu, D.R., Aravind, L. & Rao, A. (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science, 324, 930–935.
151. Thol, F., Damm, F., Lüdeking, A., Winschel, C., Wagner, K., Morgan, M., Yun, H., Göhring, G., Schlegelberger, B., Hoelzer, D., Lübbert, M., Kanz, L., Fiedler, W., Kirchner, H., Heil, G., Krauter, J., Ganser, A. & Heuser, M. (2011) Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. Journal of Clinical Oncology, 29, 2889–2896.
152. Traina, F., Visconte, V., Elson, P., Tabarroki, A., Jankowska, A.M., Hasrouni, E., Sugimoto, Y., Szpurka, H., Makishima, H., O'Keefe, C.L., Sekeres, M.A., Advani, A.S., Kalaycio, M., Copelan, E.A., Saunthararajah, Y., Olalla Saad, S.T., Maciejewski, J.P. & Tiu, R.V. (2014) Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia, 28, 78–87.
153. Vassiliou, G.S., Cooper, J.L., Rad, R., Li, J., Rice, S., Uren, A., Rad, L., Ellis, P., Andrews, R., Banerjee, R., Grove, C., Wang, W., Liu, P., Wright, P., Arends, M. & Bradley, A. (2011) Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice. Nature Genetics, 43, 470–475.
154. Walter, M.J., Ding, L., Shen, D., Shao, J., Grillot, M., McLellan, M., Fulton, R., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., Kandoth, C., Baty, J., Westervelt, P., DiPersio, J.F., Mardis, E.R., Wilson, R.K., Ley, T.J. & Graubert, T.A. (2011) Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia, 25, 1153–1158.
155. Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., Yang, H., Gross, S., Artin, E., Saada, V., Mylonas, E., Quivoron, C., Popovici-Muller, J., Saunders, J.O., Salituro, F.G., Yan, S., Murray, S., Wei, W., Gao, Y., Dang, L., Dorsch, M., Agresta, S., Schenkein, D.P., Biller, S.A., Su, S.M., de Botton, S. & Yen, K.E. (2013) Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science, 340, 622–626.
156. Ward, P.S., Patel, J., Wise, D.R., Abdel-Wahab, O., Bennett, B.D., Coller, H.A., Cross, J.R., Fantin, V.R., Hedvat, C.V., Perl, A.E., Rabinowitz, J.D., Carroll, M., Su, S.M., Sharp, K.A., Levine, R.L. & Thompson, C.B. (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell, 17, 225–234.
157. Wei, A., Tan, P., Perruzza, S., Govindaraj, C., Fleming, S., McManus, J., Avery, S., Patil, S., Stevenson, W., Plebanski, M. & Spencer, A. (2015) Maintenance lenalidomide in combination with 5-azacytidine as post remission therapy for acute myeloid leukemia. British Journal of Haematology, 169, 199–210.
158. Whitman, S.P., Archer, K.J., Feng, L., Baldus, C., Becknell, B., Carlson, B.D., Carroll, A.J., Mrózek, K., Vardiman, J.W., George, S.L., Kolitz, J.E., Larson, R.A., Bloomfield, C.D. & Caligiuri, M.A. (2001) Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Research, 61, 7233–7239.
159. Wolleschak, D., Mack, T.S., Perner, F., Frey, S., Schnöder, T.M., Wagner, M.C., Höding, C., Pils, M.C., Parkner, A., Kliche, S., Schraven, B., Hebel, K., Brunner-Weinzierl, M., Ranjan, S., Isermann, B., Lipka, D.B., Fischer, T. & Heidel, F.H. (2014) Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function. Haematologica, 99, e90–e93.
160. Wouters, B.J., Löwenberg, B., Erpelinck-Verschueren, C.A., van Putten, W.L., Valk, P.J. & Delwel, R. (2009) Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood, 113, 3088–3091.
161. Xie, M., Lu, C., Wang, J., McLellan, M.D., Johnson, K.I., Wendl, M.C., McMichael, J.F., Schmidt, H.K., Yellanpatula, V., Miller, C.A., Ozenberger, B.A., Welch, J.S., Link, D.C., Walter, M., Mardis, E.R., Dipersio, J.F., Chen, F., Wilson, R.K., Ley, T.J. & Ding, L. (2014) Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nature Medicine, 20, 1472–1478.
162. Zarrinkar, P.P., Gunawardane, R.N., Cramer, M.D., Gardner, M.F., Brigham, D., Belli, B., Karaman, M.W., Pratz, K.W., Pallares, G., Chao, Q., Sprankle, K.G., Patel, H.K., Levis, M., Armstrong, R.C., James, J. & Bhagwat, S.S. (2009) AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood, 114, 2984–2992.
163. Zirm, E., Spies-Weisshart, B., Heidel, F., Schnetzke, U., Böhmer, F.D., Hochhaus, A., Fischer, T. & Scholl, S. (2012) Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation. British Journal of Haematology, 157, 483–492.
164. Ziv, O., Zeisel, A., Mirlas-Neisberg, N., Swain, U., Nevo, R., Ben-Chetrit, N., Martelli, M.P., Rossi, R., Shiesser, S., Canman, C.E., Carell, T., Geacintov, N., Falini, B., Domany, E. & Livneh, Z. (2014) Identification of novel DNA-damage tolerance genes reveals regulation of translesion DNA synthesis by nucleophosmin. Nature Communications., 5, 5437.